Pfizer's Lung Cancer Drug Fails Phase 3, CFO David Denton Departs
PFE is trading near its 52-week low of $23.11 (7.1% above the low) on elevated volume (2.2× avg).
Summary
Pfizer's experimental lung cancer drug, sigvotatug vedotin, failed to meet its overall survival endpoint in a Phase 3 trial for metastatic non-squamous NSCLC, causing shares to slide. This pipeline setback is compounded by the departure of CFO David Denton, who has left to join Nike. These negative developments contrast with recent positive news regarding Pfizer's other pipeline assets and strong Q1 results. The drug failure impacts future revenue potential, while the CFO's exit creates leadership uncertainty. Investors should watch the Q2 earnings call on August 4th for more details on these impacts and the CFO transition.
At the time of this announcement, PFE was trading at $24.74 on NYSE in the Life Sciences sector, with a market capitalization of approximately $140.9B. The 52-week trading range was $23.11 to $28.75. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.